UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the month of ~~February~~March 2026

Commission file number 001-41291

Meihua International Medical Technologies Co., Ltd.

(Translation of registrant’s name into English)

88 Tongda Road, Touqiao Town

Guangling District, Yangzhou, 225000

People’s Republic of China

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒  Form 40-F  ☐

~~Entry~~Nasdaq ~~into~~Delisting ~~the Leak-Out Agreement~~Decision

As previously disclosed, ~~on January 22, 2026, each of the purchasers in the private placements that~~ Meihua International Medical Technologies Co., Ltd. ~~offered~~(the on“Company”) ~~October~~received 8a ~~and~~notice ~~December 5,~~from ~~2025~~The ~~(collectively,~~Nasdaq ~~the~~Stock Market (the “~~Purchasers~~Nasdaq”) ~~entered~~on ~~into~~December a2, ~~lock-up~~2025, ~~agreement~~notifying (the ~~“Lock-Up~~Company ~~Agreement”)~~that ~~with~~ the ~~Company, pursuant~~Nasdaq staff had determined to ~~which~~delist the ~~Purchasers~~Company’s securities ~~agreed~~from ~~not~~the toNasdaq ~~offer,~~in ~~sell,~~accordance orwith ~~otherwise~~its ~~dispose~~authority ofunder ~~any~~Nasdaq ~~securities~~Listing ofRule ~~the~~5815(c). The Company’s ~~(the~~class ~~“Securities”)~~A ordinary ~~for~~shares awere ~~period~~subsequently ofsuspended ~~twelve~~from ~~(12)~~trading ~~months~~on ~~following~~Nasdaq ~~the~~and ~~applicable~~started ~~closing,~~trading ~~subject~~on to the ~~terms~~OTC ~~and~~Marketplace ~~conditions~~under ~~set~~the ~~forth~~symbol “MHUAF” ~~therein~~on December 9, 2025.

On January 2927, 2026, the Company ~~entered~~attended ~~into leak-out~~a ~~agreements with each Purchaser, pursuant to which the Company agrees to waive the lock-up provisions set forth in the Lock-Up~~hearing ~~Agreement~~before ~~with respect to all of~~ the ~~Securities.~~Nasdaq InHearings ~~exchange,~~Panel ~~each Purchaser agreed to limit resales of~~ (the ~~Securities~~“Panel”) ~~during the lock-up period~~ to noappeal ~~more than 15% of~~ the ~~average~~delisting ~~daily trading volume over the prior ten trading days~~determination.

AOn ~~form~~February of24, 2026, the ~~Leak-Out~~Company ~~Agreement~~received isa ~~furnished~~notice ~~hereto~~from asNasdaq, ~~Exhibit~~notifying ~~99.1~~the ~~and~~Company ~~such~~that ~~document~~the isPanel ~~incorporated~~had ~~herein~~determined byto ~~reference.~~deny ~~The foregoing is only a brief description of~~ the ~~material terms~~Company’s ofrequest ~~the Leak-Out Agreement and does not purport~~ to bereinstate atrading ~~complete~~on ~~description~~Nasdaq ~~of the rights~~ and determined ~~obligations~~to ofdelist the ~~parties~~Company’s ~~thereunder and is qualified in its entirety by reference to such exhibit~~securities.

~~Exhibits~~On March 2, 2026, the Company requested the Nasdaq Listing and Hearing Review Council to review the Panel’s delisting decision.

Exhibit No.		Description
99.1		Form of the Leak-Out Agreement

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Meihua International Medical Technologies Co., Ltd.
By:	/s/ Leyi Lee
Name:	Leyi Lee
Title:	Chief Executive Officer
Date: February 2, 2026
Date: March 2, 2026

Filing Compare · Meihua International Medical Technologies Co., Ltd.